evidence table
Citicoline Cognition Randomized Trial Evidence Table
Structured evidence table for Citicoline Cognition Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Citicoline Cognition Randomized Trial | van der Flier et al., 2018 Iadecola et al., 2019 Iadecola, 2013 Collaborators, 2022 Medina-Rioja et al., 2024 Venkat et al., 2015 Mok et al., 2024 Vascular cognitive impairment (VCI) refers to cognitive dysfunction mainly caused by cerebrovascular disease and its risk factors, ranging from subtle cognitive decline to dementia (;). | 1 | Miao Jingchao (2026) | Efficacy and safety of Ginkgo biloba leaf extract injection for vascular cognitive impairment: a systematic review and meta-analysis |
| Citicoline Cognition Randomized Trial | Skrobot et al., 2018 Ip et al., 2024 Mok et al., 2024 Swartz et al., 2025 McShane et al., 2019 Smith et al., 2020 Battle et al., 2021 Gorelick et al., 2011 O'Brien and Thomas, 2015 Current treatments for VCI focus primarily on controlling vascular risk factors such as hypertension, diabetes, and dyslipidemia (;;;). | 1 | Miao Jingchao (2026) | Efficacy and safety of Ginkgo biloba leaf extract injection for vascular cognitive impairment: a systematic review and meta-analysis |
| Citicoline Cognition Randomized Trial | However, there has been no systematic quality assessment or evidence synthesis of published RCTs. | 1 | Miao Jingchao (2026) | Efficacy and safety of Ginkgo biloba leaf extract injection for vascular cognitive impairment: a systematic review and meta-analysis |
| Citicoline Cognition Randomized Trial | It can be caused by cerebral small vessel disease, large artery infarctions, and chronic cerebral hypoperfusion (). | 1 | Miao Jingchao (2026) | Efficacy and safety of Ginkgo biloba leaf extract injection for vascular cognitive impairment: a systematic review and meta-analysis |
| Citicoline Cognition Randomized Trial | Growing evidence indicates that neuropathological changes associated with Alzheimer’s disease (AD) begin decades before clinical symptoms emerge, highlighting the importance of targeting the prodromal and even preclinical stages as a critical treatment window []. | 4 | Özge Aynur (2026) | The Real-World Early Neuroprotective Effects of Oral Citicoline Combination in Prodromal Dementia |
| Citicoline Cognition Randomized Trial | Mild cognitive impairment (MCI), often conceptualized as prodromal dementia, represents a transitional state where timely neuroprotective strategies may be associated with preservation of neuronal integrity and a slower trajectory toward overt dementia []. | 4 | Özge Aynur (2026) | The Real-World Early Neuroprotective Effects of Oral Citicoline Combination in Prodromal Dementia |
| Citicoline Cognition Randomized Trial | Clinical studies on age-related memory impairment, vascular cognitive impairment, and early Alzheimer’s-type decline suggest that citicoline use may be associated with better performance in attention, memory, and executive functions [,,]. | 4 | Özge Aynur (2026) | The Real-World Early Neuroprotective Effects of Oral Citicoline Combination in Prodromal Dementia |
| Citicoline Cognition Randomized Trial | 1 2 The global increase in dementia prevalence has intensified interest in interventions that could alter the course of cognitive decline before irreversible neurodegeneration sets in. | 4 | Özge Aynur (2026) | The Real-World Early Neuroprotective Effects of Oral Citicoline Combination in Prodromal Dementia |
Source documents